Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

  1. Bidard, F.-C.
  2. Kaklamani, V.G.
  3. Neven, P.
  4. Streich, G.
  5. Montero, A.J.
  6. Forget, F.
  7. Mouret-Reynier, M.-A.
  8. Sohn, J.H.
  9. Taylor, D.
  10. Harnden, K.K.
  11. Khong, H.
  12. Kocsis, J.
  13. Dalenc, F.
  14. Dillon, P.M.
  15. Babu, S.
  16. Waters, S.
  17. Deleu, I.
  18. García Sáenz, J.A.
  19. Bria, E.
  20. Cazzaniga, M.
  21. Lu, J.
  22. Aftimos, P.
  23. Cortés, J.
  24. Liu, S.
  25. Tonini, G.
  26. Laurent, D.
  27. Habboubi, N.
  28. Conlan, M.G.
  29. Bardia, A.
  30. Mostrar todos os autores +
Revista:
Journal of Clinical Oncology

ISSN: 1527-7755,  0732-183X

Ano de publicación: 2022

Volume: 32

Tipo: Artigo

DOI: 10.1200/JCO.22.00338 GOOGLE SCHOLAR lock_openAcceso aberto editor
Fonte de datos: Scopus